Janus Henderson Group PLC Sells 329,362 Shares of Neogen Co. (NASDAQ:NEOG)

Janus Henderson Group PLC reduced its holdings in Neogen Co. (NASDAQ:NEOG - Free Report) by 9.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,303,645 shares of the company's stock after selling 329,362 shares during the quarter. Janus Henderson Group PLC owned about 1.52% of Neogen worth $40,107,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in NEOG. Barclays PLC grew its position in Neogen by 129.8% during the third quarter. Barclays PLC now owns 366,753 shares of the company's stock worth $6,165,000 after buying an additional 207,160 shares in the last quarter. Procyon Advisors LLC grew its position in Neogen by 22.3% during the fourth quarter. Procyon Advisors LLC now owns 35,513 shares of the company's stock worth $431,000 after buying an additional 6,467 shares in the last quarter. Avanza Fonder AB acquired a new stake in Neogen during the fourth quarter worth about $169,000. Inspire Investing LLC grew its position in Neogen by 30.9% during the fourth quarter. Inspire Investing LLC now owns 36,383 shares of the company's stock worth $442,000 after buying an additional 8,580 shares in the last quarter. Finally, Blue Trust Inc. grew its position in Neogen by 196.7% during the fourth quarter. Blue Trust Inc. now owns 3,368 shares of the company's stock worth $41,000 after buying an additional 2,233 shares in the last quarter. 96.73% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CAO John Patrick Moylan bought 10,000 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was bought at an average price of $5.07 per share, for a total transaction of $50,700.00. Following the completion of the purchase, the chief accounting officer now owns 10,000 shares of the company's stock, valued at approximately $50,700. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Aashima Gupta bought 16,000 shares of the business's stock in a transaction dated Monday, May 12th. The stock was purchased at an average price of $6.25 per share, with a total value of $100,000.00. Following the purchase, the director now directly owns 21,917 shares of the company's stock, valued at $136,981.25. The trade was a 270.41% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 83,500 shares of company stock worth $431,525 over the last quarter. Company insiders own 1.13% of the company's stock.

Neogen Price Performance

NEOG traded up $0.05 during midday trading on Friday, reaching $6.61. 3,484,738 shares of the company's stock were exchanged, compared to its average volume of 3,017,816. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -3.02 and a beta of 1.83. The company has a quick ratio of 2.46, a current ratio of 3.77 and a debt-to-equity ratio of 0.33. Neogen Co. has a one year low of $3.87 and a one year high of $18.58. The business has a 50-day simple moving average of $6.75 and a two-hundred day simple moving average of $10.35.

Neogen (NASDAQ:NEOG - Get Free Report) last announced its quarterly earnings results on Wednesday, April 9th. The company reported $0.10 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.02). The business had revenue of $221.00 million for the quarter, compared to the consensus estimate of $225.27 million. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The firm's revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.12 EPS. As a group, research analysts predict that Neogen Co. will post 0.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Guggenheim decreased their target price on Neogen from $15.00 to $13.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Piper Sandler decreased their target price on Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 22nd.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.